Literature DB >> 18070872

Amisulpride-induced neuroleptic malignant syndrome.

Ercan Abay, Rugul Kose.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070872     DOI: 10.1176/jnp.2007.19.4.488

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


× No keyword cloud information.
  6 in total

1.  Acute rhabdomyolysis during treatment with amisulpride and metformin.

Authors:  Francesco Ursini; Elena Succurro; Alessandro Grembiale; Franco Arturi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-18       Impact factor: 2.953

Review 2.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Lethal neuroleptic malignant syndrome due to amisulpride.

Authors:  Frank Musshoff; Elke Doberentz; Burkhard Madea
Journal:  Forensic Sci Med Pathol       Date:  2013-03-16       Impact factor: 2.007

Review 4.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

5.  Olanzapine-Induced Neuroleptic Malignant Syndrome.

Authors:  Seyedhamze Hosseini; Forouzan Elyasi
Journal:  Iran J Med Sci       Date:  2017-05

6.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.